BRIEF published on 11/26/2025 at 00:51, 11 months 9 days ago CureVac annonce les résultats de son assemblée générale extraordinaire Assemblée Générale Extraordinaire BioNTech Approbation Des Actionnaires CureVac Fusion Légale
BRIEF published on 11/26/2025 at 00:51, 11 months 9 days ago CureVac Announces Results of Extraordinary General Meeting BioNTech Extraordinary General Meeting CureVac Shareholders Approval Legal Merger
PRESS RELEASE published on 11/26/2025 at 00:46, 11 months 9 days ago CureVac Announces Voting Results of Extraordinary General Meeting CureVac announces approval of BioNTech's exchange offer for outstanding shares at Extraordinary General Meeting with over 99.16% approval rate BioNTech MRNA Technology Exchange Offer CureVac EGM Voting Results
BRIEF published on 11/24/2025 at 13:15, 11 months 11 days ago CureVac publie ses résultats financiers du troisième trimestre et des neuf premiers mois de 2025 Performance Financière CureVac Technologie De L'ARNm Résultats Du Troisième Trimestre 2025 Fusion BioNTech
BRIEF published on 11/24/2025 at 13:15, 11 months 11 days ago CureVac Reports Q3 and Nine-Month Financial Results for 2025 Financial Performance MRNA Technology CureVac Q3 2025 Results BioNTech Merger
PRESS RELEASE published on 11/24/2025 at 13:10, 11 months 11 days ago CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates CureVac announces financial results for Q3 and first nine months of 2025, BioNTech transaction progresses, EMA clearance received for cancer therapy CVHNLC sqNSCLC Financial Results Cancer Therapy CureVac BioNTech Transaction EMA Clearance
BRIEF published on 08/15/2025 at 13:32, 1 year 2 months ago CureVac Reports Q2 and H1 2025 Financial Results; Announces Key Developments Financial Results MRNA Technology CureVac Patent Resolution BioNTech Acquisition
BRIEF published on 08/15/2025 at 13:32, 1 year 2 months ago CureVac publie ses résultats financiers du deuxième trimestre et du premier semestre 2025 et annonce des développements clés Résultats Financiers CureVac Technologie De L'ARNm Résolution De Brevet Acquisition De BioNTech
PRESS RELEASE published on 08/15/2025 at 13:27, 1 year 2 months ago CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates CureVac announces Q2 2025 financial results, business updates & agreement with BioNTech for transformative mRNA treatments. Strong cash position Financial Results BioNTech CureVac MRNA Q2 2025
BRIEF published on 08/08/2025 at 02:20, 1 year 2 months ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
Published on 11/05/2026 at 14:31, 44 minutes ago First Breach Close-Quarters Strike (CQS) Drone Successfully Completes Full Mission Profile
Published on 11/05/2026 at 14:20, 55 minutes ago Polaris Renewable Energy Declares Quarterly Dividend
Published on 11/05/2026 at 14:15, 1 hour ago Loar Holdings Inc. Reports Q3 2026 Record Results and Upward Revision to 2026 Outlook and Full Year 2027 Outlook
Published on 11/05/2026 at 14:00, 1 hour 15 minutes ago Horizon Aircraft Signs MOU With Constance Lake First Nation to Bring Lifesaving Medical Aircraft to Remote and Isolated Indigenous Communities
Published on 11/05/2026 at 14:58, 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/05/2026 at 14:56, 18 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 11/05/2026 at 15:01, 13 minutes ago Chiffre d'Affaires du 1er semestre de l'exercice 2026/2027
Published on 11/05/2026 at 10:16, 4 hours 58 minutes ago Accélération confirmée au troisième trimestre 2026 Tous les métiers en croissance, chiffre d’affaires en progression de +6,5 %
Published on 11/05/2026 at 10:16, 4 hours 58 minutes ago Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%
